https://orcid.org/0000-0001-5916-6337
References
- LeWinter MM. Acute pericarditis. N Engl J Med. 2014 Dec 18;371(25):2410–2416.
- Adler Y, Charron P, Imazio M, et al. 2015 ESC guidelines for the diagnosis and management of pericardial diseases: the task force for the diagnosis and management of pericardial diseases of the European Society of Cardiology (ESC) Endorsed by: the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015 Nov 7;36(42):2921–2964.
- Imazio M, Brucato A, DeRosa FG, et al. Aetiological diagnosis in acute and recurrent pericarditis: when and how. J Cardiovasc Med. 2009 Mar 1;10(3):217–230.
- Imazio M, Gaita F, LeWinter M. Evaluation and treatment of pericarditis: a systematic review. Jama. 2015 Oct 13;314(14):1498–1506.
- Imazio M, Bobbio M, Cecchi E, et al. Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (COlchicine for REcurrent pericarditis) trial. Arch Internal Med. 2005 Sep 26;165(17):1987–1991.
- Imazio M, Brucato A, Cemin R, et al. Colchicine for recurrent pericarditis (CORP) a randomized trial. Ann Intern Med. 2011 Oct 4;155(7):409–414.
- Imazio M, Belli R, Brucato A, et al. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. Lancet. 2014 Jun 28;383(9936):2232–2237.
- Maestroni S, Di Corato PR, Cumetti D, et al. Recurrent pericarditis: autoimmune or autoinflammatory? Autoimmun Rev. 2012 Nov 1;12(1):60–65.
- Cantarini L, Imazio M, Brizi MG, et al. Role of autoimmunity and autoinflammation in the pathogenesis of idiopathic recurrent pericarditis. Clin Rev Allergy Immunol. 2013 Feb;44(1):6–13.
- Kuemmerle-Deschner JB, Lohse P, Koetter I, et al. NLRP3 E311K mutation in a large family with Muckle-Wells syndrome-description of a heterogeneous phenotype and response to treatment. Arthritis Res Ther. 2011 Dec;13(6):1–9.
- Dinarello CA, Van Der Meer JW Treating inflammation by blocking interleukin-1 in humans. In Seminars in immunology 2013 Dec 15 (Vol. 25, No. 6, pp. 469–484). Academic Press. https://doi.org/10.1016/j.smim.2013.10.008.
- Finetti M, Insalaco A, Cantarini L, et al. Long-term efficacy of interleukin-1 receptor antagonist (anakinra) in corticosteroid-dependent and colchicine-resistant recurrent pericarditis. J Pediatr. 2014 Jun 1;164(6):1425–1431.
- Jain S, Thongprayoon C, Espinosa RE, et al. Effectiveness and safety of anakinra for management of refractory pericarditis. Am J Cardiol. 2015 Oct 15;116(8):1277–1279.
- Dagan A, Langevitz P, Shoenfeld Y, et al. Anakinra in idiopathic recurrent pericarditis refractory to immunosuppressive therapy; a preliminary experience in seven patients. Autoimmun Rev. 2019 Jun 1;18(6):627–631.
- Brucato A, Imazio M, Gattorno M, et al. Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence: the AIRTRIP randomized clinical trial. Jama. 2016 Nov 8;316(18):1906–1912.
- Imazio M, Andreis A, De Ferrari GM, et al. Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: the IRAP (International registry of Anakinra for pericarditis) study. Eur J Prev Cardiol. 2020 Jun 1;27(9):956–964.